The objective of the proposed study is to understand the oncogenic role of MUC1 glycoprotein in the development and progression of infiltrating ductal adenocarcinoma of the pancreas (PDA) from preinvasive neoplasias (PanlNs) to invasive adenocarcinomas, and to evaluate the efficacy of MUC1-targeted therapeutic intervention for the treatment and/or prevention of this devastating disease. MUC1 (CD227) is a membrane tethered mucin glycoprotein overexpressed and aberrantly glycosylated in >60% of human ductal pancreatic adenocarcinoma. Tumor-associated MUC1 is known to be associated with the metastatic phenotype of cancer cells. MUC1 is recently identified as a potential oncogene, and has been an active target for therapeutic intervention in several cancers including PDA. Over expression of MUC1 in PDA has long been known, but its function has been difficult to elucidate, partly due to the lack of appropriate models. With the advent of siRNA technology and the recent development of a mouse model of PDA, we can begin to fully elucidate the role of MUC1. Our hypothesis is that MUC1 plays an important oncogenic function in pancreatic cancer development and serves as a target for therapeutic intervention.
Our specific aims are 1) To determine the functional role of MUC1 in human pancreatic cancer cell lines; 2) To determine the effects on the development of PanlNs and PDA in Mud -deficient PDA mice; and 3) To evaluate the effects on the development of PanlNs and PDA in PDA mice expressing human MUC1. These mouse models provide an unique and distinctive opportunity to not only understand the role of MUC1 during pancreatic cancer development, but also offers us the ability to evaluate MUC1-targeted immune therapy in the PDA mice that expresses human MUC1 as a self-antigen. In the third aim we also propose to determine novel strategies to reduce tumor-induced immune-suppression within the tumor microenvironment to improve efficacy of targeted immune therapy. This project is extremely relevant to pancreatic cancer. These preclinical studies will form the basis for designing more efficacious and novel therapies to combat the mortality associated with PDA.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA118944-04
Application #
7700439
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Jhappan, Chamelli
Project Start
2006-07-01
Project End
2011-05-31
Budget Start
2008-11-14
Budget End
2009-05-31
Support Year
4
Fiscal Year
2008
Total Cost
$214,596
Indirect Cost
Name
University of North Carolina Charlotte
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
066300096
City
Charlotte
State
NC
Country
United States
Zip Code
28223
Wu, Shu-Ta; Williams, Chandra D; Grover, Priyanka A et al. (2018) Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004. PLoS One 13:e0193260
Yazdanifar, Mahboubeh; Zhou, Ru; Mukherjee, Pinku (2016) Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells. Curr Trends Immunol 17:95-115
Zhou, R; Curry, J M; Roy, L D et al. (2016) A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis. Oncogene 35:5608-5618
Nath, Sritama; Roy, Lopamudra Das; Grover, Priyanka et al. (2015) Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer. Pancreas 44:909-17
Nath, Sritama; Mukherjee, Pinku (2014) MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med 20:332-42
Curry, Jennifer M; Thompson, Kyle J; Rao, Shanti G et al. (2013) The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. J Surg Oncol 107:713-22
Schettini, Jorge; Kidiyoor, Amritha; Besmer, Dahlia M et al. (2012) Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. Cancer Immunol Immunother 61:2055-65
Sahraei, M; Roy, L D; Curry, J M et al. (2012) MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene 31:4935-45
Roy, L D; Sahraei, M; Subramani, D B et al. (2011) MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 30:1449-59
Besmer, Dahlia M; Curry, Jennifer M; Roy, Lopamudra D et al. (2011) Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res 71:4432-42

Showing the most recent 10 out of 14 publications